LONDON – Heptares Therapeutics Ltd. signed a deal worth a potential £65 million (US$106.3 million) with Takeda Pharmaceutical Co., to characterize the structure and deliver early leads against a G-protein coupled receptor (GPCR) that is involved in schizophrenia.